Serina Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	0.14	0.03	0.14	0.36	1.73	1.4	1.4	1.67
Revenue Growth (YoY)	317.65%	-76.39%	-60.11%	-79.11%	23.78%	-0.57%	-15.73%	-
Cost of Revenue	0.04	0.01	0.02	0.03	0.24	0.36	0.17	0.3
Gross Profit	0.1	0.02	0.13	0.34	1.48	1.03	1.24	1.36
Selling, General & Admin	9.33	5.97	6.71	6.72	8.14	5.65	3.87	5.62
Research & Development	0.73	1.03	1.46	3.71	5.9	5.83	5.78	8.48
Other Operating Expenses	-0.08	-0.01	-0.55	-0.11	0	0.8	-1.75	0
Operating Expenses	9.98	6.98	7.61	10.33	14.04	12.28	7.9	14.1
Operating Income	-9.88	-6.96	-7.49	-10	-12.56	-11.25	-6.66	-12.74
Interest Expense / Income	4.9	3.34	1.1	0.4	-0.03	0	0.01	0.03
Other Expense / Income	0.03	0.17	0.09	0.47	-0.52	-3.74	-0.1	2.73
Pretax Income	-14.8	-10.46	-8.68	-10.87	-12.01	-7.5	-6.58	-15.49
Income Tax	0	0	0	0	0.15	0	0	0
Net Income	-14.8	-10.46	-8.68	-10.87	-12.15	-7.5	-6.58	-15.49
Shares Outstanding (Basic)	1	1	1	1	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1	1	1	1	1
Shares Change	-	0.16%	0.58%	1.07%	6.75%	13.93%	6.40%	-
EPS (Basic)	-13.72	-9.70	-8.09	-10.20	-11.61	-7.39	-7.39	-18.99
EPS (Diluted)	-13.72	-9.70	-8.09	-10.20	-11.61	-7.39	-7.39	-18.99
Free Cash Flow	-7.8	-5.94	-7.86	-7.84	-10.8	-8.02	-6.29	-8.45
Free Cash Flow Per Share	-7.23	-5.50	-7.29	-7.32	-10.19	-8.07	-7.21	-10.32
Gross Margin	71.83%	61.76%	86.81%	92.80%	85.88%	73.93%	88.03%	81.75%
Operating Margin	-6954.93%	-20476.47%	-5197.92%	-2768.70%	-726.79%	-805.52%	-474.57%	-764.65%
Profit Margin	-10424.65%	-30770.59%	-6024.31%	-3009.70%	-703.36%	-537.39%	-468.66%	-929.89%
Free Cash Flow Margin	-5492.96%	-17467.65%	-5454.86%	-2170.91%	-625.06%	-574.21%	-447.72%	-507.20%
EBITDA	-9.77	-7	-7.45	-9.21	-11.08	-6.97	-5.89	-14.62
EBITDA Margin	-6881.69%	-20573.53%	-5171.53%	-2550.14%	-641.44%	-499.07%	-419.23%	-877.67%
Depreciation & Amortization	0.13	0.13	0.13	1.26	0.95	0.54	0.68	0.85
EBIT	-9.9	-7.13	-7.58	-10.46	-12.04	-7.5	-6.57	-15.47
EBIT Margin	-6973.94%	-20961.76%	-5262.50%	-2897.78%	-696.47%	-537.39%	-467.81%	-928.39%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).